Joohyuk Sohn
Joohyuk Sohn is a Yonsei breast oncologist and investigator on the DESTINY-Breast and TROPION trials.
Joohyuk Sohn leads breast medical oncology trials at Yonsei Cancer Center, including HER2-low, TROP2 ADC, and CDK4/6 studies with Korean cohorts.
Patients with hormone-receptor-positive metastatic breast cancer that has stopped responding to endocrine therapy can be offered trastuzumab deruxtecan as their first chemotherapy-type treatment if the tumour shows any HER2 staining, rather than waiting until after conventional chemotherapy. Whether to use it before or after chemotherapy is now a choice, since overall survival was not shown to differ and the drug carries a risk of lung inflammation.
Patients whose breast cancer was previously called HER2-negative may now be eligible for an effective HER2-directed drug if their tumour has even low-level HER2 staining, so pathology reports must now distinguish HER2-low (1+ or 2+/ISH-negative) from HER2-zero. This applies to metastatic disease after at least one line of chemotherapy; it does not mean these patients benefit from trastuzumab or other older HER2 drugs.
Women with hormone-receptor-positive, HER2-negative breast cancer that has spread to lymph nodes and has other high-risk features can now be offered two years of abemaciclib alongside their hormone therapy, with a durable reduction in relapse. It does not apply to node-negative or low-risk disease, and the diarrhoea and cost are real trade-offs to discuss.
Pages like this
not linked directly; found by shared links- PersonSara M. Tolaney
Shares monarchE: two years of abemaciclib after surgery in high-risk, hormone-receptor-positive early breast cancer, Datopotamab deruxtecan, TROP2, Trastuzumab deruxtecan.
- PersonKan Yonemori
Shares DESTINY-Breast06: trastuzumab deruxtecan before any chemotherapy in hormone-receptor-positive, HER2-low or ultralow breast cancer, Trastuzumab deruxtecan, HER2-positive breast cancer, HR-positive / HER2-negative breast cancer.
- PersonYeon Hee Park
Shares DESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable group, Trastuzumab deruxtecan, HER2, HER2-positive breast cancer.
- PersonSung-Bae Kim
Shares DESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable group, Trastuzumab deruxtecan, HER2, HER2-positive breast cancer.
- ProductTrastuzumab duocarmazine
Shares Trastuzumab deruxtecan, HER2, HER2-positive breast cancer.
- PersonBinghe Xu
Shares DESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable group, TROP2, HER2, HER2-positive breast cancer.
- PersonGiuseppe Curigliano
Shares DESTINY-Breast06: trastuzumab deruxtecan before any chemotherapy in hormone-receptor-positive, HER2-low or ultralow breast cancer, Trastuzumab deruxtecan, HER2, HR-positive / HER2-negative breast cancer.
- IdeaUse the brain's own transport door to carry antibody drugs across
Shares TROP2, Trastuzumab deruxtecan, HER2, HER2-positive breast cancer.